Notably, a case report described an exceptional response to BMS-986158 (BETi) in a patient with BRD4-NUTM1 NUT carcinoma harboring a BRD4 splice-site mutation, highlighting the potential for personalized BET-targeted therapy (173). The gene discussed is BRD4; the disease is nut midline carcinoma.